PAION Annual General Meeting and CeNeS Acquisition Update
Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Aachen, 6 May 2008 - The biopharmaceutical company PAION AG (FSE PA8,
ISIN DE000A0B65S3), today announced that during their Annual General
Meeting held yesterday, the resolutions proposed by the management
board and supervisory board were adopted with large majorities. The
results are available at the company's website www.paion.de/hv.
In addition, PAION notes that the Scheme Document which sets out,
amongst other things, the full terms and conditions of the proposed
acquisition of CeNeS Pharmaceuticals plc has been posted to CeNeS'
shareholders and will be available shortly at www.paion.de/investors.
###
About PAION
PAION is a biopharmaceutical company specializing in developing and
commercializing innovative drugs for the treatment of thrombotic
diseases, that is, diseases caused by the obstruction of a blood
vessel by a blood clot. Currently, PAION's focus is on the causal
treatment of acute ischemic stroke. PAION intends to build and expand
its portfolio of drug candidates using a "search-and-development"
approach. Accordingly, PAION seeks to identify promising new
compounds, license or otherwise acquire them and advance them through
the clinical development and regulatory approval process. Where
appropriate, particularly during the late stages of the clinical
development and approval process and the commercialization phase,
PAION seeks to collaborate with experienced partners.
Disclaimer
On April 10, 2008, PAION announced a recommended offer for the entire
issued and to be issued share capital of CeNeS Pharmaceuticals plc.
Therefore the Company is currently in an offer period as defined by
the Takeover Code of the UK Panel on Takeovers and Mergers. Because
of this, shareholders need to be aware of certain additional
reporting requirements regarding transactions in PAION shares. For
further information, please see the full text of the acquisition
announcement published on April 10, 2008, and the press release
explaining the additional reporting requirements published on April
14, 2008, both of which are available on PAION's website at
www.paion.de/investors.
This communication is neither an offer to buy securities nor a
solicitation for an offer to sell securities. Securities may not be
offered or sold in the United States absent registration or an
exemption from registration. There will be no public offer of the
shares of PAION AG in the United States.
Contact
Dr. Peer Nils Schroeder, Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Tel. +49 241 4453-152
E-mail pn.schroeder@paion.de
www.paion.de
--- End of Message ---
PAION AG
Martinstrasse 10 - 12 Aachen Germany
WKN: A0B65S; ISIN:
DE000A0B65S3; Index: Prime All Share, CDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Amtlicher
Markt in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Stuttgart;
